Interviews

There is a lot of drug switching that's happening, whether it's for medical or nonmedical reasons, said Steven Deitelzweig, MD, system chairman of hospital medicine at Ochsner Clinical School, professor of medicine at the University of Queensland.

With nearly a third of patients post-myocardial infarction (MI) developing heart failure, prevention is very important, said Javed Butler, MD, MPH, MBA, professor of medicine at University of Mississippi, president of the Baylor Scott & White Research Institute.

Catherine Nester, RN, vice president of physician and patient strategies at Inozyme Pharma, highlights the importance of newborn screening for rare diseases and the impact of the BeginNGS diagnostic tool.

Lucio Gordan, MD, president and managing physician, Florida Cancer Specialists & Research Institute (FCS), discusses how FCS has learned to adapt during difficult times, including COVID-19, Hurricane Ian, and current drug shortages.

Jennifer Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia Center at Dana-Farber Cancer Institute, discussed the uptake of zanubrutinib for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).

Researchers and organizations must collaborate to address the persistent disparities in access to treatments for multiple myeloma, explained Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation.

Attendees should look out for results from the STEP HFpEF program and HEART-FID trial at the European Society of Cardiology (ESC) Congress 2023, said Stephen Greene, MD, Duke University Medical Center and the Duke Clinical Research Institute.

Joseph Aracri, DO, Allegheny Health Network, spoke with The American Journal of Managed Care® about preventing respiratory syncytial virus (RSV) through immunoglobulin-based treatments and everyday actions.

Crystal Denlinger, MD, FACP, incoming CEO of the National Comprehensive Cancer Network (NCCN), talks about the organization’s challenges and solutions to keeping up with the ever-changing oncology landscape and improving patient access to guideline-recommended treatments.

Neil Goldfarb, president and CEO of the Greater Philadelphia Business Coalition on Health (GPBCH), previews the upcoming GPBCH Wellness Summit taking place on September 14, 2023.

Stephen Kingsmore, MD, DSc, shares the exciting advancement of the BeginNGS newborn genomic sequencing program as it approaches the end of phase 2.

Gustavo Fonseca, MD, FACP, physician director of clinical research, Florida Cancer Specialists & Research Institute (FCS), discusses the results from a late phase complexity analysis on barriers to clinical trials regarding biopsy requirements.

Jennifer Gass, PhD, FACMG, associate director, Genetics Laboratory, Florida Cancer Specialists & Research Institute, discusses the recent Genetics Laboratory, which focuses on next-generation sequencing (NGS) testing in oncology care.

Greater attention needs to be on educating patients who are switching from a reference product they are successful on to a biosimilar than a patient who is starting a treatment with a biosimilar at the beginning of their disease journey, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.

Olalekan Ajayi, PharmD, MBA, 2023-2024 president of the Association of Community Cancer Centers, discusses what practices should do to succeed under the Enhancing Oncology Model (EOM).

Jeff Patton, MD, CEO of OneOncology, joins Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 3 of "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."

BeginNGS aims to enable the prompt identification of potential genetic disease with its newborn screening program.

Stephen Nicholls, PhD, MBBS, Monash University and Victorian Heart Hospital, explains how he works closely with patients and study sites in SURPASS-CVOT to avoid weight loss drug discontinuation and weight regain.

Sheila Garland, PhD, MSc, Memorial University in Newfoundland, Canada talks about the cognitive effects cancer can have on patients, beyond treatment side effects, and the direct impacts these can make on patients’ lives and care.

In his explanation of the tremelimumab priming dose, Ghassan Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, also reviews and analogizes checkpoint inhibitors as a whole.

There is a right way and a wrong way to inform a patient about a switch from the reference product to a biosimilar, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.

Debra Patt, MD, PhD, MBA, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."

G.B. John Mancini, MD, University of British Columbia, goes into detail about the recruitment process of the VICTORION-2-PREVENT trial, which focuses on inclisiran to reduce cardiovascular risk.

Some populations face longer diagnostic delays for hidradenitis suppurativa (HS), but medical education can help improve knowledge of common dermatologic diseases and reduce delays in diagnosis, said Haley Naik, MD, FAAD, associate professor of dermatology, University of California, San Francisco, School of Medicine.

Ghassan Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, expands on findings that durvalumab plus tremelimumab demonstrated an overall survival benefit at 4 years for certain patients with unresectable hepatocellular carcinoma.

Stephen Nicholls, PhD, MBBS, Monash University and Victorian Heart Hospital, expands on the patient characteristics and potential impacts of COVID-19 on SURPASS-CVOT, the phase 3 cardiovascular outcomes trial for tirzepatide.

On this episode of Managed Care Cast, we speak with the lead researcher from a study published in the July 2023 issue of The American Journal of Managed Care® on whether social determinants of health is a predictor for identifying high-cost utilizers among those with commercial health insurance.

Dayna Johnson, PhD, MPH, MSW, MS talks about the necessity of community partnerships as the recipient of this year’s Associated Professional Sleep Societies (APSS) Diversity, Equity, and Inclusion Leadership Award at SLEEP 2023 and how inquiring into the community is vital for integrating healthy sleep practices.